Our Vision
To improve global human health by providing long-term immunity for some of the world’s most pressing diseases.
Emergex Vaccines is a clinical stage, privately-held, biotechnology company headquartered in Abingdon in the UK, and focused on addressing some of the world’s most immediate health threats, including viral diseases such as Dengue Fever, Zika, Ebola and pandemic Flu, as well as serious intra-cellular bacterial infections.
Emergex is developing a pipeline of innovative CD8+ T-Cell priming vaccines that have the potential to deliver fast, broad and long lasting immunity to reduce serious illness associated with infectious diseases.
Emergex’s vaccines are entirely synthetic, which means that they do not require biological steps to be manufactured, and in turn do not introduce live viruses, RNA or DNA into people. An added benefit is that synthetic vaccines can be stored at ambient temperature, avoiding the need for refrigeration or freezing and making vaccination much more convenient all around the world. Our T-Cell vaccine candidates have also been designed to be delivered trans-dermally, avoiding the need for traditional needles and intra-muscular injections.
Drawing on a rich scientific heritage and international collaborative approach, Emergex Vaccines has invested in state-of-the-art laboratories to conduct research and develop key components of its vaccines, and works closely alongside its international collaborators, including the Institute of Molecular and Cell Biology (IMCB) of Singapore, Bio-Manguinhos/FioCruz in Brazil, and George Mason University in the US
Technologies
We combine validated technologies with the latest scientific advances to develop our vaccines, including using synthetic peptide codes selected and determined through experiments on actual pathogen infected cells and using a proprietary quantum-sized nanocluster carrier system for delivery of these codes. Our technologies are advantageous in numerous ways.
Business Model
Our business model is focused on developing vaccines that reduce morbidity and mortality against existing and newly emerging infectious outbreaks for use by governments (National Health Services), non-governmental organisations and the public.
Our activities have generated interest from governments, non-governmental organisations and charities who are interested in developing vaccines. These include:
- The Singapore Health Department, who will carry out preclinical and clinical studies on Dengue fever
- The Brazilian Health Department, who will carry out preclinical and clinical studies for Zika, Dengue and Yellow Fever
We have signed an agreement with the Institute of Molecular and Cell Biology (IMCB) to develop a vaccine for the highly contagious Hand, Foot & Mouth Disease. IMCB is a research institute in Singapore that is part of the government Agency for Science, Technology and Research (A*STAR).
We are forming partnerships with pharmaceutical companies to generate both milestone and future royalty revenue streams on retail sales of vaccines.
Watch our video on how we are pioneering a new approach to vaccine development and manufacturing.
